Maria Elisa Mancuso: During Day 2 of the Annual EHC Conference We Discussed Very Rare Bleeding Disorders!
Maria Elisa Mancuso, Senior Hematology Consultant at Humanitas Research Hospital, shared on LinkedIn:
”During Day 2 of the Annual EHC Conference in Vienna we discussed very rare bleeding disorders as fibrinogen defects (thanks to Alessandro Casini) and the “newly recognized” group of Bleeding Disorders of Unknown Cause – BDUC (thanks to Johanna Gebhart).
Congratulations to Dominik Cepic for is wonderful overview and passionate advocacy for hemophilia B with inhibitors as “rare among rares”.
The SLAM session shed lights to many important issues as orthopedic evaluation and care of arthropathy, treatment of PUPs, pain and ITI.
During the session dedicated to gene therapy real world experience (Wolfgang Miesbach), struggles in procurement and reimbursement (Gaetan Duport) and new non-AAV mediated gene therapies (Paul Batty) were discussed.
Finally the day was beautifully close by the energy of the youth debates.”
More from EHC 2025 featured in Hemostasis Today.
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story
-
Jul 2, 2026, 18:59Indu Thakur: Supporting Blood Donation Through Public Awareness in MSBT
-
Jul 2, 2026, 18:47Vee Townsend: IMHUE Highlights 9 Myths and Facts About Hemophilia B
-
Jul 2, 2026, 17:17Nico Gagelmann: Launching Myths and Facts on Hematology and Cell Therapy
-
Jul 2, 2026, 17:05Haroun Gajraj: Understanding the Technology Behind Spider Vein Treatment
-
Jul 2, 2026, 16:44Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
-
Jul 2, 2026, 16:22Introducing a New Resource for the ITP Community – ITP Support Association